Welcome to our dedicated page for Hcw Biologics news (Ticker: HCWB), a resource for investors and traders seeking the latest updates and insights on Hcw Biologics stock.
HCW Biologics Inc. develops fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune disorders, proinflammatory diseases, cancer and senescence-associated dysplasia. Its recurring company updates center on the TOBI and TRBC discovery platforms and product candidates such as HCW9302, an IL-2 fusion immunotherapeutic, HCW11-018b, a T-cell engager for solid tumors, and HCW9206, a multi-cytokine fusion protein reagent used in CAR-T manufacturing research.
News about HCWB also covers clinical and preclinical program disclosures, research publications, licensing activity involving HCW11-006 and Trimmune, operating and financial results, capital-structure matters, shareholder voting topics and Nasdaq listing-status developments.
HCW Biologics (HCWB) entered an exclusive distribution agreement with Akron Biotech to commercialize its multi‑cytokine fusion reagent HCW11-006 for CAR-T cell production.
The agreement includes pre-payment commitments for product sales, with HCW Biologics supplying research and cGMP-grade HCW11-006 and Akron marketing and distributing it through its global network of advanced therapy developers, biopharma companies, and research institutions. HCW11-006, built on HCW Biologics’ TRBC platform, is designed to generate highly functional, long-lived T-memory stem cell–enriched CAR-T products for cancer, autoimmune and infectious disease applications.
Preclinical studies cited in the release showed CAR-T cells produced with HCW11-006 had stronger anti-tumor and antiviral activity and improved persistence versus CAR-Ts manufactured using standard αCD3/28/IL-2-based methods.
HCW Biologics (HCWB) received a U.S. Patent and Trademark Office Notice of Allowance for claims covering use of its lead immunotherapeutic HCW9302 to treat alopecia areata.
This allowance adds to four recently issued U.S. patents protecting HCW9302 compositions, nucleic acids, vectors, and methods for treating autoimmune diseases. HCW9302 is an IL‑2‑based fusion immunotherapeutic designed to preferentially expand regulatory T cells. A Phase 1 dose‑escalation trial of HCW9302 monotherapy in alopecia areata remains on track for full readout in Q4 2026, is reported to be well tolerated with no dose‑limiting toxicities, and early data from the first two dose cohorts show encouraging responses after a single 3 micrograms/kg dose.
HCW Biologics (NASDAQ: HCWB) reported that a TGF-β trap and IL-15 fusion has been identified, with collaborators, as a novel moiety with potential applications against diseased cells and viral infections. Human studies showed this fusion expanded progenitor CD8+ T cells and NK cells, was well tolerated in cancer patients, and provided clinical benefit. Preclinical models also showed activity against HIV-1 and bronchopulmonary dysplasia.
According to HCW Biologics, this TGF-β/IL-15 moiety has been incorporated into its second-generation fusion immunotherapeutics built on its TRBC platform. Lead TCE candidate HCW11-018b combines the moiety with a tissue factor–targeting BiTE, while lead ICI candidate HCW11-040 links the moiety to pembrolizumab. Both programs are at IND-enabling stage, with clinical studies planned for 2027.
HCW Biologics (NASDAQ: HCWB) reported second quarter 2026 results and business updates, combining clinical progress, partnering activity and financing steps. For Q2 2026, revenue rose to $135,568 from $6,550, while six‑month 2026 revenue increased to $6.7 million, largely from closing the Trimmune licensing agreement and related services. Q2 2026 net loss widened to $5.2 million versus $1.9 million a year earlier, but six‑month 2026 net loss narrowed to $1.7 million from $4.1 million.
HCW reported preliminary Phase 1 data for HCW9302 in alopecia areata, with all three patients in the second dose cohort showing ≥25% SALT score reductions and no dose‑limiting toxicities. The company also advanced its T‑cell engager HCW11‑018b toward a planned IND by requesting a Type B FDA meeting.
HCW re‑acquired ex vivo rights to two HCW9206‑related molecules and is seeking partners to commercialize them as CAR‑T manufacturing reagents. It raised roughly $5.6 million in two Q2/Q3 2026 private placements involving insiders, reclassified certain warrants to equity, and settled a $1.7 million liability for $1.2 million. Management nonetheless stated there is substantial doubt about the company’s ability to continue as a going concern without additional funding. HCW regained Nasdaq bid‑price compliance and executed a one‑for‑six reverse stock split on June 30, 2026.
HCW Biologics (NASDAQ: HCWB) priced a $1.6 million private placement of 618,682 units with investors that include company officers, a director and an existing stockholder. Each unit consists of one common share (or one pre-funded warrant) plus the right to receive one common stock purchase warrant, subject to stockholder approval.
HCW Biologics will issue 218,682 common shares and 400,000 pre-funded warrants at combined prices of $2.585 per share unit and $2.5849 per pre-funded warrant unit. Pre-funded warrants are immediately exercisable at $0.0001 and do not expire; common warrants, once approved and issued, will allow purchase of up to 618,682 shares at $2.585 per share for 5.5 years. Proceeds are intended to fund the HCW9302 clinical trial, IND-enabling studies for T-Cell Engager HCW11-018b and immune checkpoint inhibitor HCW11-040, and general corporate purposes. A registration rights agreement requires filing a Form S-1 within 15 trading days and seeking SEC effectiveness within 60 days; each investor’s ownership is capped at 9.99% of outstanding shares.
HCW Biologics (NASDAQ: HCWB) reported key milestones for its proprietary tetravalent second-generation T-cell engager program and plans to start clinical trials in the first half of 2027. The company has requested a Type B pre-IND meeting with the U.S. FDA to discuss development and regulatory strategy for its investigational lead candidate HCW11-018b, a subcutaneously administered T-cell engager created using its TRBC drug development platform.
According to HCW Biologics, HCW11-018b is designed to treat solid tumors that overexpress human tissue factor, including gynecologic and pancreatic cancers, by targeting tissue factor-expressing cells, activating CD3-positive effector T cells, and reducing immunosuppression in the tumor microenvironment. Extensive preclinical work, including in vitro and in vivo potency, antigen specificity, pharmacokinetics, nonhuman primate toxicity, and therapeutic window assessments, indicated robust, sustained, antigen-specific tumor killing, enhanced CD8⁺ T-cell activation and tumor infiltration, and an absence of cytokine release syndrome within the therapeutic dose range.
The company also reported establishing a robust, streamlined, and cost-efficient manufacturing process using high-producing recombinant CHO cell lines and a proprietary monoclonal antibody for affinity purification, which is being produced under GMP standards by a top-tier CDMO to support planned clinical development and potential future commercialization.
HCW Biologics (Nasdaq: HCWB) has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, following a Nasdaq Hearings Panel decision on June 29, 2026. The company is now compliant with all continued listing requirements and will be subject to a mandatory monitoring period through June 17, 2027.
To support long-term compliance, HCW Biologics plans to effect a one-for-six reverse stock split on June 30, 2026.
HCW Biologics (NASDAQ: HCWB) approved a 1-for-6 reverse stock split of its common stock, effective 12:01 a.m. ET on June 30, 2026. Shares will continue trading on Nasdaq under “HCWB” on a split-adjusted basis with new CUSIP 40423R303.
The move is intended to help maintain compliance with Nasdaq Listing Rule 5550(a) Bid Price Rule and other Nasdaq Hearings Panel conditions. Outstanding shares will be reduced from 9,581,079 to approximately 1,596,849, with no change to authorized shares or par value. Fractional shares will be rounded up to whole shares.
HCW Biologics (NASDAQ:HCWB) reported preliminary human data from a Phase 1, dose-escalation trial of HCW9302 monotherapy in alopecia areata. In the 3 μg/kg cohort, all three mild alopecia patients achieved ≥25% SALT score reductions after a single subcutaneous dose, with only mild, self-limiting adverse events.
No capillary leak, cytokine release syndrome, or eosinophil increases were reported. Dose escalation, including an 8 μg/kg cohort, is ongoing, and the company aims to define the Recommended Phase 2 Dose by year-end 2026, with potential expansion into other autoimmune and inflammatory indications.
HCW Biologics (NASDAQ:HCWB) exercised its option to regain full ex vivo rights to HCW9206 and HCW9201 from Wugen for no cost, while keeping the original upfront license fee and 2.2 million Wugen shares.
HCW9206 is a commercial-ready, multi-cytokine fusion protein reagent that, according to published data, may improve CAR-T and NK-cell manufacturing efficiency, enrich long-lived T-memory stem cells, and potentially enhance persistence and function of CAR-T therapies. The company plans to commercialize these reagents through partners focused on CAR-T and NK-cell therapies.